Harvard Bioscience Inc. (NASDAQ: HBIO)

Introduction

Harvard Bioscience Inc., founded in 1901, develops, manufactures, and markets life-science equipment for research, drug discovery, and preclinical testing. Headquartered in Holliston, Massachusetts, the company serves academic institutions, contract research organizations, and pharmaceutical and biotechnology companies worldwide.

Corporate Structure

• Employees: Approximately 500 total; ~300 based in the U.S.
• Manufacturing Facilities:
  • New Brighton, Minnesota
  • Holliston, Massachusetts
  • Reutlingen, Germany
  • Barcelona, Spain
  • March, Germany
• Subsidiaries (12 brands): Biochrom, BioDrop, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, Multi Channel Systems (MCS), Panlab, Warner Instruments, among others.
• Leadership Team:
  • James Green, Chairman, President & CEO (since July 2019)
  • Mark Frost, Interim CFO & Treasurer (appointed April 10, 2025)
  • John Fry, Chief Legal Counsel
  • Diane Houston, VP, Information Technology
  • Lori Packer, VP, Global People Operations
  • Nitya Shetty, VP, Global R&D
  • Ryan Wallace, SVP, Global Sales (Preclinical Systems)

Recent Developments

CFO Transition (April 10, 2025)

• Jennifer Cote notified of her resignation effective upon the filing of the Quarterly Report on Form 10-Q (expected by May 12, 2025).
• Mark Frost, who has over 30 years of finance experience, was named Interim CFO & Treasurer.

Conflict Minerals Disclosure (May 27, 2025)

• Filed Form SD covering January 1–December 31, 2024.
• Exhibit 1.01 attaches the Conflict Minerals Report, detailing supply chain sourcing and compliance under SEC Rule 13p-1.

Ownership Reports

• May 14, 2025: Leviticus Partners LP disclosed ownership of 4,333,817 shares (9.8% of outstanding common stock as of March 5, 2025).
• May 15, 2025: Harvey Partners LLC disclosed ownership of 2,187,500 shares (4.96% of outstanding common stock as of March 31, 2025).

Financial and Strategic Analysis

Stock Performance (as of May 29, 2025)

• Price: $0.6470 (up 127.58%)
• Volume: 167,381,797 shares
• 52-Week Range: $0.28 – $3.60
• Market Cap: $29.01 M

Key Financial Metrics

Metric	Value
Enterprise Value	$51.63 M
Price/Sales (TTM)	0.14
Price/Book (MRQ)	0.85
Revenue (TTM)	$91.4 M
Net Income (TTM)	– $58.05 M
EPS (TTM)	– 1.31
Total Cash (MRQ)	$5.55 M
Total Debt/Equity (MRQ)	300.69%
Profit Margin (TTM)	– 63.52%
Return on Assets (TTM)	– 2.38%
Return on Equity (TTM)	– 138.80%

Strategic Context

• Product Segments: Fluidics; Laboratory Equipment & Supplies; Molecular Analysis; Cell Analysis; Physiology.
• Regulatory Compliance: Conflict minerals reporting under SEC Rule 13p-1.
• Partnerships: Distribution agreements with major industry players (e.g., GE Healthcare, Thermo Fisher Scientific).

Market Position and Industry Context

• Customer Base: Universities, government labs, biotech, and pharmaceutical firms, CROs.
• Global Reach: Direct and distribution channels in over 100 countries.
• Competitive Landscape: Competes with other scientific instrument manufacturers in preclinical and life-science research tools.

tl;dr

• On April 10, 2025, CFO Jennifer Cote announced her resignation; Mark Frost was appointed Interim CFO.
• Filed Form SD with the Conflict Minerals Report on May 27, 2025, covering the 2024 calendar year.
• Share price increased by 127.58% to $0.6470 as of May 29, 2025, on significant trading volume.
• Leviticus Partners LP holds 9.8% and Harvey Partners LLC holds 4.96% of common stock.
• 1-year target estimate stands at $3.00 per share.